Breaking News

Financial Report: Elan

July 24, 2013

Completes Tysabri transaction

Elan
 
2Q Revenues:
$56.3 million ($0.2 million 2Q12)

2Q Earnings: $2.3 billion (loss of $28.5 million 2Q12)

YTD Revenues: $56.5 million (n/a)

YTD Earnings: $2.4 billion (loss of $60.3 million YTD12)

Comments: Results included $2.5 billion income from the transfer of Tysabri to partner Biogen. Under the Tysabri transaction, Elan received an upfront payment of $3.3 billion and will continue to receive royalties on Tysabri in-market sales. Earnings in the quarter includes a net loss from continuing operations of $251.8 million ($90.0 million 2Q12) and net income from discontinued operations of $2.5 billion. YTD earnings includes a net loss from continuing operations of $324.6 million ($164.7 million YTD12), and net income from discontinued operations of $2.7 billion ($104.4 million in YTD12) related to the Tysabri, Prothena and EDT businesses. According to a board announcement in June, Elan is in the process of exploring the sale of the company.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks